Open AccessSafety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial
Author(s) -
Asghar Amini Harandi,
Roya Abolfazli,
A. Hatemian,
K. Ghragozlee,
M. Ghaffarpour,
Maryam Karimi,
S. Shahbegi,
Hossein Pakdaman,
M. Tabasi,
A. L. Tabatabae,
Alireza Nourian
Publication year - 2011
Publication title -
stroke research and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.939
H-Index - 34
eISSN - 2090-8105
pISSN - 2042-0056
DOI - 10.4061/2011/721613
Subject(s) - medicine , placebo , tolerability , stroke (engine) , clinical trial , adverse effect , placebo group , ischemic stroke , anesthesia , alternative medicine , ischemia , mechanical engineering , pathology , engineering
Objective. To investigate the safety and efficacy of MLC601 (NeuroAid) as a traditional Chinese medicine on motor recovery after ischemic stroke. Methods. This study was a double-blind, placebo-controlled clinical trial on 150 patients with a recent (less than 1 month) ischemic stroke. All patients were given either MLC601 (100 patients) or placebo (50 patients), 4 capsules 3 times a day, as an add-on to standard stroke treatment for 3 months. Results. Sex, age, elapsed time from stroke onset, and risk factors in the treatment group were not significantly different from placebo group at baseline (P>.05). Repeated measures analysis showed that Fugl-Meyer assessment was significantly higher in the treatment group during 12 weeks after stroke (P<.001). Good tolerability to treatment was shown, and adverse events were mild and transient. Conclusion. MLC601 showed better motor recovery than placebo and was safe on top of standard ischemic stroke medications especially in the severe and moderate cases
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom